Developer docs
API playgroundTry for free, no card

Search company profiles

Torrent Pharmaceuticals

Full company profile

uuid0000jnl

Namestring
Torrent Pharmaceuticals
Legal namestring
Torrent Pharmaceuticals Ltd.
Company typeenum
Public
Founded yearint
1971
Descriptiontext

Torrent Pharmaceuticals Limited is an India-based, publicly listed pharmaceutical company (BSE: 500420, NSE: TORNTPHARM) founded in 1971 and headquartered in Ahmedabad, Gujarat, with FY2026 turnover of Rs 13,980 crore. The company focuses on therapeutic segments of cardiovascular, central nervous system, gastro-intestinal, diabetology, women's healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. It pioneered the niche marketing concept in India and operates a 6,800+ field force reaching 2 lakh+ doctors through 27 sales divisions, supported by 5,800+ stockists and 59,000+ retailers via 23 distribution centers.

The company manufactures generic and specialty pharmaceutical formulations across 16 manufacturing plants, including USFDA-approved API and formulation facilities, an oncology plant, a dermatology-exclusive plant, and an exclusive insulin contract-manufacturing unit for Novo Nordisk at Indrad. Its R&D Centre at Bhat, Gujarat houses 999 scientists, supported by 660+ research staff overall, with proprietary drug delivery technologies including Dual Retard Inlay, Gastro Retentive System, Long Acting Injectables, Nasal Drug Delivery, and Topical Foams. The patent portfolio comprises 1,279 filings with 689 granted globally, and the US pipeline includes 120 ANDA approvals with 19 pending.

Torrent generates revenue through branded generic sales in India, international operations across 50+ countries via wholly owned subsidiaries in 14 nations (ranked #1 Indian company in Brazil and Germany, #5 overall in Germany), consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca), and contract manufacturing. Growth has been accelerated by acquisitions including Elder Pharma (2014), Zyg Pharma (2015), Glochem (2016), Unichem (2017), Bio-Pharm US (2018), Curatio Healthcare (2022), and J.B. Chemicals & Pharmaceuticals (Jan 2026, Rs 12,537 crore). The Mehta family holds 68.31% promoter shareholding, with Samir Mehta as Chairman and Aman Mehta as Managing Director heading India and RoW business.

Short descriptiontext

Torrent Pharmaceuticals is an India-based, publicly listed pharma company manufacturing generic and specialty formulations across cardiovascular, CNS, GI, diabetology, dermatology, and oncology, serving 2 lakh+ doctors in India and operating in 50+ countries, with FY2026 revenue of Rs 13,980 crore.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersAhmedabad, India
HQ citystring
Ahmedabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices20 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, branded formulations, cardiovascular therapeutics, diabetes medications, consumer healthcare brands
Industry4 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Domestic Formulations (India)
TypeOne Time License
Description

Sale of branded generic pharmaceutical products in India across therapeutic segments including cardiovascular, CNS, gastro-intestinal, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, diabetology, pain management, gynaecology, oncology and anti-infective. India business generated Rs 2,215 crore in Q4 FY26 with 43% YoY growth.

torrentpharma.com
2International Business
TypeOne Time License
Description

Operations across US, Europe (Germany, UK, Malta), Brazil and Rest of World markets through wholly owned subsidiaries. US business has 120 ANDAs approved with 19 in pipeline. Germany ranked #1 among Indian players and 5th in market. Brazil ranked #1 in covered market.

torrentpharma.com
3Contract Manufacturing
TypeOne Time License
Description

Exclusive formulation and packaging unit for manufacturing Insulin for Novo Nordisk since early 1990s at Indrad facility

torrentpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Sembolic
Description

Oral semaglutide brand launched March 2026 for diabetes and weight management

businesstoday.in
+7 more records
Core offering1 text field

Torrent Pharmaceuticals manufactures and markets branded generic and generic pharmaceutical formulations across therapeutic segments including cardiovascular, central nervous system, gastro-intestinal, diabetology, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. The company also sells consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca) and operates contract manufacturing for partners including Novo Nordisk.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Q4 FY26 revenue grew 42% YoY to Rs 4,197 crore driven by JB Chemicals acquisition and strong domestic performance
+3 more records
Product overview1 text field

Torrent Pharmaceuticals operates as a leading pharmaceutical company with a diversified portfolio spanning therapeutic areas including Cardiovascular (CV), Central Nervous System (CNS), Gastro-Intestinal (GI), Diabetology, Women Healthcare (WHC), Vitamins Minerals & Nutrients (VMN), Cosmo-Dermatology, Nephrology, Oncology, and Anti-Infective segments. The company offers consumer healthcare brands (Tedibar baby care, Shelcal calcium supplements, Unienzyme digestive enzymes, Ahaglow skincare, Prozuca diabetes nutrition) alongside a comprehensive range of prescription pharmaceutical products. Major product lines include oral anti-diabetics (Azulix, Azukon, Voglitor, Piopod, Dibeta), cardiovascular medications, and weight management solutions (Orlica). Recent significant launches include generic semaglutide brands Sembolic and Semalix for diabetes and obesity treatment.

Product and service13 records
1Sembolic
CategoryPharmaceutical Product
Description

Oral semaglutide generic formulation for diabetes and weight management, launched as the first generic oral version in India.

2Semalix
CategoryPharmaceutical Product
Description

Injectable semaglutide generic formulation for diabetes and weight management, launched alongside Sembolic.

3Tedibar
CategoryConsumer Healthcare Brand
Description

Consumer healthcare brand for baby skincare including diaper rash cream, bathing bar, body wash, and ceramide-based moisturizing products.

4Shelcal
CategoryConsumer Healthcare Brand
Description

Calcium and vitamin D3 supplement brand available in tablet, gummy, and total health formulations for bone and overall health.

5Unienzyme
CategoryConsumer Healthcare Brand
Description

Digestive enzyme supplement brand with multi-enzyme formula for digestive health support.

6Ahaglow
CategoryConsumer Healthcare Brand
Description

Dermatological skincare brand including face wash gel and skin repair gel with Ectoin and marine botanicals.

7Prozuca
CategoryConsumer Healthcare Brand
Description

Nutritional supplement designed for individuals with diabetes to meet their nutritional needs.

8Azulix
CategoryPharmaceutical Product
Description

Glimepiride-based oral anti-diabetic medication available in 1-4mg strengths, also in combination with metformin (MF variants).

9Azukon
CategoryPharmaceutical Product
Description

Gliclazide-based oral anti-diabetic medication for type 2 diabetes management.

10Voglitor
CategoryPharmaceutical Product
Description

Voglibose-based alpha-glucosidase inhibitor for diabetes management, available in MD and MF formulations.

11Piopod
CategoryPharmaceutical Product
Description

Pioglitazone-based oral anti-diabetic agent, also available in combination formulations with glimepiride and metformin.

12Dibeta
CategoryPharmaceutical Product
Description

Metformin-based oral anti-diabetic medication available in sustained release (SR) formulation.

13Orlica
CategoryPharmaceutical Product
Description

Orlistat-based anti-obesity medication available in 60mg and 120mg tablet formulations.

Scale indicator21 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Torrent Pharmaceuticals entered into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to commercialize its novel gastrointestinal drug

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2023-01-01
Description

Torrent and Zydus signed licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India

3Boehringer Ingelheim India
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2022-01-01
Description

Co-marketing partnership with Boehringer Ingelheim India Private Limited to co-market its anti-diabetic drug and fixed dose combinations in India

torrentpharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Acquired four brands from Dr. Reddy's - 'Styptovit-E', 'Finast', 'Finast-T', and 'Dynapress'

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Licensing agreement with Medicine Patent Pool to manufacture and commercialize generic version of Pfizer Oral COVID-19 Treatment

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Voluntary Licensing Agreement with Lilly to manufacture and distribute Baricitinib for Covid-19 treatment in India

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Introduced MSD and Ridgeback's molnupiravir under brand name Molnutor® in India for Covid-19 treatment

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2019-01-01
Description

Licensing agreement for co-marketing of Remogliflozin Etabonate in India for diabetes treatment

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

Licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2009-01-01
Description

License and supply agreement with AstraZeneca for marketing its products in international market. Also entered into research collaboration with AstraZeneca for developing novel anti-hypertensive drug.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2005-01-01
Description

Torrent Pharma has been the only Indian contract manufacturer of insulin for Novo Nordisk since early 1990s, operating a dedicated formulation and packaging facility at Indrad, Gujarat. This long-standing partnership demonstrates Torrent's manufacturing excellence and regulatory compliance.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sun Pharmaceutical Industries
TypeDirect peer
Description

India's largest pharma company with a broad specialty and generics portfolio overlapping Torrent's CV, CNS, GI and chronic therapy focus; most direct Indian pharma comparable by scale and geographic mix.

TypeDirect peer
Description

Large Indian generics and specialty pharma company with overlapping respiratory, cardiovascular and anti-infective portfolios and similar emerging-market distribution strengths.

TypeDirect peer
Description

Indian pharma major with comparable generics portfolio across CV, GI and oncology, plus US ANDA pipeline; historic supplier of brands acquired by Torrent in 2022.

TypeDirect peer
Description

Indian pharma company with overlapping therapy areas (CV, diabetology, CNS, women's health) and comparable US generics presence; closely comparable business model.

TypeDirect peer
Description

Indian pharma peer with strong India generics, biosimilars and US business; co-marketing partner with Torrent for Saroglitazar Mg, making it both a peer and a commercial partner.

TypeDirect peer
Description

Indian pharma company with overlapping diabetology and chronic therapy focus; co-marketing partner for Remogliflozin in India, similar emerging-market profile.

TypeDirect peer
Description

Indian generics heavyweight with extensive US ANDA portfolio and similar broad therapeutic coverage; comparable scale and contract manufacturing exposure.

TypeDirect peer
Description

Indian pharma company with strong domestic acute and chronic portfolio in similar therapeutic areas (CV, anti-infectives, GI); closely comparable India field-force-driven model.

TypeDirect peer
Description

Leading Indian domestic pharma company with strong field-force-driven model across chronic and acute therapies; overlapping consumer healthcare (OTC) and chronic prescription segments.

TypeBroad incumbent
Description

Global generics incumbent with broad portfolio in the same therapy areas; competes with Torrent in US ANDAs, Europe and emerging markets and is a useful scale benchmark.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance14 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Torrent Pharmaceuticals

Generic Pharmaceuticalstorrentpharma.com

Torrent Pharmaceuticals is an India-based, publicly listed pharma company manufacturing generic and specialty formulations across cardiovascular, CNS, GI, diabetology, dermatology, and oncology, serving 2 lakh+ doctors in India and operating in 50+ countries, with FY2026 revenue of Rs 13,980 crore.

What Torrent Pharmaceuticals does

Torrent Pharmaceuticals Limited is an India-based, publicly listed pharmaceutical company (BSE: 500420, NSE: TORNTPHARM) founded in 1971 and headquartered in Ahmedabad, Gujarat, with FY2026 turnover of Rs 13,980 crore. The company focuses on therapeutic segments of cardiovascular, central nervous system, gastro-intestinal, diabetology, women's healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. It pioneered the niche marketing concept in India and operates a 6,800+ field force reaching 2 lakh+ doctors through 27 sales divisions, supported by 5,800+ stockists and 59,000+ retailers via 23 distribution centers.

The company manufactures generic and specialty pharmaceutical formulations across 16 manufacturing plants, including USFDA-approved API and formulation facilities, an oncology plant, a dermatology-exclusive plant, and an exclusive insulin contract-manufacturing unit for Novo Nordisk at Indrad. Its R&D Centre at Bhat, Gujarat houses 999 scientists, supported by 660+ research staff overall, with proprietary drug delivery technologies including Dual Retard Inlay, Gastro Retentive System, Long Acting Injectables, Nasal Drug Delivery, and Topical Foams. The patent portfolio comprises 1,279 filings with 689 granted globally, and the US pipeline includes 120 ANDA approvals with 19 pending.

Torrent generates revenue through branded generic sales in India, international operations across 50+ countries via wholly owned subsidiaries in 14 nations (ranked #1 Indian company in Brazil and Germany, #5 overall in Germany), consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca), and contract manufacturing. Growth has been accelerated by acquisitions including Elder Pharma (2014), Zyg Pharma (2015), Glochem (2016), Unichem (2017), Bio-Pharm US (2018), Curatio Healthcare (2022), and J.B. Chemicals & Pharmaceuticals (Jan 2026, Rs 12,537 crore). The Mehta family holds 68.31% promoter shareholding, with Samir Mehta as Chairman and Aman Mehta as Managing Director heading India and RoW business.

Torrent Pharmaceuticals firmographics

Firmographics
Name
Torrent Pharmaceuticals
Legal name
Torrent Pharmaceuticals Ltd.
Website
https://torrentpharma.com
Company type
Public
Founded year
1971
Operating status
Operating
Headcount range
10,001+ employees
Short description
Torrent Pharmaceuticals is an India-based, publicly listed pharma company manufacturing generic and specialty formulations across cardiovascular, CNS, GI, diabetology, dermatology, and oncology, serving 2 lakh+ doctors in India and operating in 50+ countries, with FY2026 revenue of Rs 13,980 crore.
Ownership category
akta.pro rank

Torrent Pharmaceuticals industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Branded formulations
  • Cardiovascular therapeutics
  • Diabetes medications
  • Consumer healthcare brands

Where Torrent Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Ahmedabad
HQ country
India
HQ region
Asia

Offices20 records

Markets served

Torrent Pharmaceuticals business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Domestic Formulations (India): Sale of branded generic pharmaceutical products in India across therapeutic segments including cardiovascular, CNS, gastro-intestinal, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, diabetology, pain management, gynaecology, oncology and anti-infective. India business generated Rs 2,215 crore in Q4 FY26 with 43% YoY growth.
  2. International Business: Operations across US, Europe (Germany, UK, Malta), Brazil and Rest of World markets through wholly owned subsidiaries. US business has 120 ANDAs approved with 19 in pipeline. Germany ranked #1 among Indian players and 5th in market. Brazil ranked #1 in covered market.
  3. Contract Manufacturing: Exclusive formulation and packaging unit for manufacturing Insulin for Novo Nordisk since early 1990s at Indrad facility

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Torrent Pharmaceuticals product offering

Product offering

Core offering

Torrent Pharmaceuticals manufactures and markets branded generic and generic pharmaceutical formulations across therapeutic segments including cardiovascular, central nervous system, gastro-intestinal, diabetology, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. The company also sells consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca) and operates contract manufacturing for partners including Novo Nordisk.

Product overview

Torrent Pharmaceuticals operates as a leading pharmaceutical company with a diversified portfolio spanning therapeutic areas including Cardiovascular (CV), Central Nervous System (CNS), Gastro-Intestinal (GI), Diabetology, Women Healthcare (WHC), Vitamins Minerals & Nutrients (VMN), Cosmo-Dermatology, Nephrology, Oncology, and Anti-Infective segments. The company offers consumer healthcare brands (Tedibar baby care, Shelcal calcium supplements, Unienzyme digestive enzymes, Ahaglow skincare, Prozuca diabetes nutrition) alongside a comprehensive range of prescription pharmaceutical products. Major product lines include oral anti-diabetics (Azulix, Azukon, Voglitor, Piopod, Dibeta), cardiovascular medications, and weight management solutions (Orlica). Recent significant launches include generic semaglutide brands Sembolic and Semalix for diabetes and obesity treatment.

Differentiator

Problem solved

Functional benefit

Brands

  • Sembolic: Oral semaglutide brand launched March 2026 for diabetes and weight management
  • Semalix
  • Tedibar
  • Shelcal
  • Unienzyme
  • Ahaglow
  • Prozuca
  • Heumann

Products and services

  • Sembolic Oral semaglutide generic formulation for diabetes and weight management, launched as the first generic oral version in India.
  • Semalix Injectable semaglutide generic formulation for diabetes and weight management, launched alongside Sembolic.
  • Tedibar Consumer healthcare brand for baby skincare including diaper rash cream, bathing bar, body wash, and ceramide-based moisturizing products.
  • Shelcal Calcium and vitamin D3 supplement brand available in tablet, gummy, and total health formulations for bone and overall health.
  • Unienzyme Digestive enzyme supplement brand with multi-enzyme formula for digestive health support.
  • Ahaglow Dermatological skincare brand including face wash gel and skin repair gel with Ectoin and marine botanicals.
  • Prozuca Nutritional supplement designed for individuals with diabetes to meet their nutritional needs.
  • Azulix Glimepiride-based oral anti-diabetic medication available in 1-4mg strengths, also in combination with metformin (MF variants).
  • Azukon Gliclazide-based oral anti-diabetic medication for type 2 diabetes management.
  • Voglitor Voglibose-based alpha-glucosidase inhibitor for diabetes management, available in MD and MF formulations.
  • Piopod Pioglitazone-based oral anti-diabetic agent, also available in combination formulations with glimepiride and metformin.
  • Dibeta Metformin-based oral anti-diabetic medication available in sustained release (SR) formulation.
  • Orlica Orlistat-based anti-obesity medication available in 60mg and 120mg tablet formulations.

Quantifiable outcome

  • Q4 FY26 revenue grew 42% YoY to Rs 4,197 crore driven by JB Chemicals acquisition and strong domestic performance
  • +3 more outcomes

Companies that use Torrent Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Torrent Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Torrent Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Takeda PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2024Torrent Pharmaceuticals entered into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to commercialize its novel gastrointestinal drug
  • Zydus LifesciencescoreGTM or Marketing Partner · 1 January 2023Torrent and Zydus signed licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India
  • Boehringer Ingelheim IndiacoreGTM or Marketing Partner · 1 January 2022Co-marketing partnership with Boehringer Ingelheim India Private Limited to co-market its anti-diabetic drug and fixed dose combinations in India
  • Dr. Reddy's LaboratoriesminorChannel Partner/ Reseller/ Distributor · 1 January 2022Acquired four brands from Dr. Reddy's - 'Styptovit-E', 'Finast', 'Finast-T', and 'Dynapress'
  • Medicine Patent PoolcoreStrategic or Co-development Partner · 1 January 2022Licensing agreement with Medicine Patent Pool to manufacture and commercialize generic version of Pfizer Oral COVID-19 Treatment
  • Eli Lilly (Lilly)coreStrategic or Co-development Partner · 1 January 2021Voluntary Licensing Agreement with Lilly to manufacture and distribute Baricitinib for Covid-19 treatment in India
  • Merck & Co. (MSD) and Ridgeback BiotherapeuticscoreStrategic or Co-development Partner · 1 January 2021Introduced MSD and Ridgeback's molnupiravir under brand name Molnutor® in India for Covid-19 treatment
  • Glenmark PharmaceuticalscoreGTM or Marketing Partner · 1 January 2019Licensing agreement for co-marketing of Remogliflozin Etabonate in India for diabetes treatment
  • Reliance Life SciencesminorStrategic or Co-development Partner · 1 January 2013Licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
  • AstraZenecacoreStrategic or Co-development Partner · 1 January 2009License and supply agreement with AstraZeneca for marketing its products in international market. Also entered into research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
  • Novo NordiskcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2005Torrent Pharma has been the only Indian contract manufacturer of insulin for Novo Nordisk since early 1990s, operating a dedicated formulation and packaging facility at Indrad, Gujarat. This long-standing partnership demonstrates Torrent's manufacturing excellence and regulatory compliance.

Scale indicators21 records

Recent moves6 records

Expansion highlights6 records

Torrent Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Sun Pharmaceutical Industries: India's largest pharma company with a broad specialty and generics portfolio overlapping Torrent's CV, CNS, GI and chronic therapy focus; most direct Indian pharma comparable by scale and geographic mix.
  • Cipla: Large Indian generics and specialty pharma company with overlapping respiratory, cardiovascular and anti-infective portfolios and similar emerging-market distribution strengths.
  • Dr. Reddy's Laboratories: Indian pharma major with comparable generics portfolio across CV, GI and oncology, plus US ANDA pipeline; historic supplier of brands acquired by Torrent in 2022.
  • Lupin: Indian pharma company with overlapping therapy areas (CV, diabetology, CNS, women's health) and comparable US generics presence; closely comparable business model.
  • Zydus Lifesciences: Indian pharma peer with strong India generics, biosimilars and US business; co-marketing partner with Torrent for Saroglitazar Mg, making it both a peer and a commercial partner.
  • Glenmark Pharmaceuticals: Indian pharma company with overlapping diabetology and chronic therapy focus; co-marketing partner for Remogliflozin in India, similar emerging-market profile.
  • Aurobindo Pharma: Indian generics heavyweight with extensive US ANDA portfolio and similar broad therapeutic coverage; comparable scale and contract manufacturing exposure.
  • Alkem Laboratories: Indian pharma company with strong domestic acute and chronic portfolio in similar therapeutic areas (CV, anti-infectives, GI); closely comparable India field-force-driven model.
  • Mankind Pharma: Leading Indian domestic pharma company with strong field-force-driven model across chronic and acute therapies; overlapping consumer healthcare (OTC) and chronic prescription segments.

Broad incumbents

  • Viatris (Mylan): Global generics incumbent with broad portfolio in the same therapy areas; competes with Torrent in US ANDAs, Europe and emerging markets and is a useful scale benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Torrent Pharmaceuticals social profiles

Digital presence

Torrent Pharmaceuticals compliance and trust

Trust signal

Compliance14 records

Torrent Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Torrent Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Torrent Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Torrent Pharmaceuticals M&A and investment

M&A and investment

M&A7 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Torrent Pharmaceuticals

What does Torrent Pharmaceuticals do?

Torrent Pharmaceuticals manufactures and markets branded generic and generic pharmaceutical formulations across therapeutic segments including cardiovascular, central nervous system, gastro-intestinal, diabetology, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. The company also sells consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca) and operates contract manufacturing for partners including Novo Nordisk.

Is Torrent Pharmaceuticals a public or private company?

Torrent Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Torrent Pharmaceuticals founded?

Torrent Pharmaceuticals was founded in 1971. It employs 10,001+ people.

Where is Torrent Pharmaceuticals based?

Torrent Pharmaceuticals is headquartered in Ahmedabad, India, in the Asia region.

How does Torrent Pharmaceuticals make money?

Three revenue lines are on record. Domestic Formulations (India) is the primary driver. The others are international Business and contract Manufacturing.

Who are Torrent Pharmaceuticals's main competitors?

Direct peers on record are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Alkem Laboratories and Mankind Pharma. Viatris (Mylan) is listed as a broad incumbent.

Does Torrent Pharmaceuticals have an API?

No public API is recorded for Torrent Pharmaceuticals.

What industry is Torrent Pharmaceuticals in?

Torrent Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXTorrent Pharma redeems ₹100 crore unlisted NCDs on November 9, 2026Torrent Pharmaceuticals redeemed ₹100 crore in unlisted secured NCDs on November 9, 2026, as per its schedule. The repayment was disclosed to BSE and NSE under SEBI LODR Regulation 30, reducing the company's outstanding liability for that tranche.ScanXTorrent Pharma receives ₹3.12 crore GST penalty order from Tamil Nadu tax officerTorrent Pharmaceuticals received a ₹3.12 crore GST penalty order from Tiruvallur authorities for pre-acquisition GST matters of JB Chemicals from FY21 to FY24. The company plans to appeal and expects no material financial impact.Business News TodayBuy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services- Moneycontrol.comGeojit Financial Services upgraded Torrent Pharmaceuticals to BUY with a target price of Rs 5,581, citing Brazil and US strength. Torrent's consolidated revenue rose 50.8% to Rs 4,979cr, EBITDA to Rs 1,666cr, but PAT fell 9.9% to Rs 544cr due to higher finance costs from the JB Pharma acquisition.Business TodayHPCL, DLF, Torrent Pharma among top picks for November; check price targets, risk reward & more - BusinessTodaySMIFS recommends buying Hindustan Petroleum, DLF, and Torrent Pharmaceuticals for November, citing eased crude prices and strong growth. HPCL has a target of Rs 371.50, DLF Rs 750, and Torrent Rs 5,000, with stop losses at Rs 325, Rs 662.50, and Rs 4,450 respectively.WhalesbookInstitutional Investors Increase Stakes in 4 Pharma StocksInstitutional investors raised stakes in Gujarat Themis Biosyn, Cipla, Torrent Pharmaceuticals, and Rubicon Research during the September quarter. Gujarat Themis Biosyn's domestic institutional holdings rose from 1.17% to 12.65%, while Torrent's consolidated revenue surged 55% and Rubicon's operating revenue grew 52%.MintFIIs and DIIs are piling into these four pharma stocks. Should you follow? | Stock Market NewsInstitutional investors increased stakes in Gujarat Themis Biosyn, Cipla, Torrent Pharmaceuticals, and Rubicon Research during the September quarter. Gujarat Themis saw FII stake rise from 1.76% to 3.8% and DII from 1.17% to 12.65%, while Torrent's revenue grew 55% to ₹4,921 crore. The article advises investors to assess valuations and risks before following institutional moves.Indian Economic ObserverSubstantial reduction in most cancer drugs' prices to come into effect from November 9 onwardsThe National Pharmaceutical Pricing Authority ordered pharmaceutical companies to reduce cancer drug prices, effective November 9. Torrent's BevakALP100 mg injection price fell from Rs 10,500 to Rs 4,523, a 57% cut, and other drugs saw similar reductions. The article notes hospital costs may still affect affordability.Ani NewsSubstantial reduction in most cancer drugs' prices to come into effect from November 9 onwardsThe National Pharmaceutical Pricing Authority ordered pharmaceutical companies to reduce cancer drug prices, effective November 9. Torrent's BevakALP injection prices fell by 57-69%, and other drugs like Erlocip and Xbira saw similar cuts. The reductions aim to lower out-of-pocket expenses for cancer patients.NDTV Profit80% Sure, 100% Wrong: The Brazil Bloodbath That Wall Street Bet Against, And What It Means For IndiaBrazil's stock market crashed 17% after Lula won the presidential runoff, while the real fell 12%. Indian companies with Brazil exposure, such as UPL and Torrent Pharma, saw minor declines, but analysts expect limited impact. The lesson is that 80% certainty can still be wrong.Business News TodayNeutral Torrent Pharma; target of Rs 4970: Motilal Oswal- Moneycontrol.comMotilal Oswal's research report on Torrent Pharma notes slightly better-than-expected revenue/EBITDA growth of 3% and 5% for the quarter, with earnings in line due to a higher tax rate. The firm values the stock at 52x forward earnings, setting a price target of INR4,970, and remains constructive on domestic growth and Semaglutide opportunities.